Autoimmune manifestations in common variable immunodeficiency.
BACKGROUND
About 20% of subjects with common variable immune deficiency (CVID) develop an autoimmune complication, most often immune thrombocytopenia or hemolytic anemia. While the pathogenesis of autoreactivity is unknown for CVID subjects in general, and to a greater extent in those with autoimmunity, there is a loss of switched memory B cells.


CONCLUSIONS
About 7-8% of CVID subjects have mutations in the transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), a significant association with this immune defect, although the same mutations may be found in normal relatives and rarely in healthy blood donors. In addition to generalized B cell dysfunction, defective elimination of autoimmune B cells has been demonstrated.
Cunningham-Rundles
C
C
Mount Sinai School of Medicine, 1425 Madison Avenue, New York City 10029, USA. Charlotte.Cunningham-Rundles@mssm.edu
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001327:Autoimmune Diseases / Q000209:etiology / Q000276:immunology; D015551:Autoimmunity / Q000235:genetics; D001402:B-Lymphocytes / Q000166:cytology* / Q000502:physiology; D002675:Child, Preschool; D017074:Common Variable Immunodeficiency / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D005260:Female; D006801:Humans; D017578:Immunoglobulin Class Switching / Q000502:physiology; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007156:Immunologic Memory / Q000235:genetics; D008297:Male; D009154:Mutation; D000069283:Rituximab; D053303:Transmembrane Activator and CAML Interactor Protein / Q000235:genetics* / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; C108467:TNFRSF13B protein, human; D053303:Transmembrane Activator and CAML Interactor Protein; D000069283:Rituximab